Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibodies Regulatory News (FAB)

Share Price Information for Fusion Antibodies (FAB)

Share Price is delayed by 15 minutes
Get Live Data
12.00    -0.50 (-4.00%)
Bid:
11.50
Ask:
12.50
Spread: 1.00 (8.696%)
Market Cap: £15.02m
FAB Live PriceLast checked at - London Stock Exchange

Intraday Fusion Antibodies Share Chart

Rule 8.3 - Fabian Romania Ltd.

22 Dec 2008 16:16

FORM 8.3

DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE

(Rule 8.3 of the Takeover Code)

1. KEY INFORMATION

Name of person dealing (Note 1) Robert Holmes on behalf of Griffin International Umbrella Fund, sub-fund Griffin Eastern European Value Fund
Company dealt in Fabian Romania Ltd.
Class of relevant security to which the dealings being disclosed relate (Note 2) Ordinary Shares
Date of dealing 19.12.2008

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long Short

Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security: Long Short

Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

(c) Rights to subscribe (Note 3)

Class of relevant security: Details

3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale Number of securities Price per unit (Note 5)
sale 3,481,482 EUR 1.00

(b) Derivatives transactions (other than options)

Product name,

e.g. CFD

Long/short (Note 6) Number of securities (Note 7) Price per unit (Note 5)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Product name,

e.g. call option

Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise

price

Type, e.g. American, European etc. Expiry

date

Option money

paid/received per unit (Note 5)

(ii) Exercising

Product name, e.g. call option Number of securities Exercise price per unit (Note 5)

(d) Other dealings (including new securities) (Note 4)

Nature of transaction (Note 8) Details Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

none

Is a Supplemental Form 8 attached? (Note 9) NO

Date of disclosure 22.12.2008
Contact name Joachim Knodt
Telephone number +350 20043252
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Notes

The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

Copyright Business Wire 2008

Date   Source Headline
22nd Jun 20267:00 amRNSNotice of allowance of patent in Canada
15th Jun 20267:00 amRNSUpdate on grant-funded DR5 project
2nd Jun 20267:00 amRNSExercise of options and total voting rights
11th May 20263:06 pmRNSHolding(s) in Company
11th May 202611:05 amRNSGrant of patent in Japan
5th May 20267:00 amRNSYear-end trading statement
30th Mar 20267:00 amRNSAntibody IP transfer agreement
17th Feb 202611:42 amRNSDirector/PDMR Shareholding
4th Feb 20263:27 pmRNSHolding(s) in Company
2nd Feb 202611:33 amRNSHolding(s) in Company
30th Jan 20265:00 pmRNSTotal Voting Rights
27th Jan 20267:05 amRNSIssue of Director Shares
27th Jan 20267:00 amRNSPlacing and Subscription to raise approx £1.4m
19th Dec 20257:00 amRNSUpdate on negotiations with NCI regarding OptiMAL
19th Dec 20257:00 amRNSUpdate on negotiations with NCI regarding OptiMAL
16th Dec 202511:04 amRNSLaunch of OptiMAL platform
11th Dec 20257:00 amRNS-RMammalian Display video
25th Nov 202512:11 pmRNSHolding(s) in Company
24th Nov 20257:00 amRNSHalf-year Financial Report
21st Nov 20257:00 amRNSNotice of Results
13th Nov 20257:00 amRNS-ROptiMAL Library video
3rd Nov 20257:00 amRNSOptiMAL® R&D Update
27th Oct 20253:38 pmRNSHolding(s) in Company
16th Oct 20251:31 pmRNSResult of AGM
16th Oct 20257:00 amRNSAGM statement and H1 trading update
8th Oct 20257:00 amRNSContract win
19th Sep 202512:58 pmRNSPosting of Annual Report & Notice of AGM
17th Sep 20257:00 amRNSOptiMAL R&D Update
8th Sep 20257:00 amRNS-RBelfast investor presentation
4th Sep 20257:00 amRNSFinal Results
28th Aug 20257:00 amRNSContract Win
27th Aug 20257:00 amRNSContract wins with existing client
26th Aug 20257:00 amRNS-RInvestor presentations
5th Aug 20257:00 amRNSGrant of U.S. Patent for OptiMAL
24th Jul 202510:56 amRNSIssue Notification: US Patent Update
11th Jul 20257:00 amRNSDirector/PDMR Shareholding
2nd Jun 20257:00 amRNSTotal Voting Rights
22nd May 20252:33 pmRNSUpdate on U.S. Patent for OptiMAL®
8th May 20257:00 amRNS-RInvestor presentation
7th May 20257:00 amRNSIssue of shares to non-executive directors
6th May 202510:53 amRNSDirector/PDMR Shareholding
6th May 202510:38 amRNSHolding(s) in Company
6th May 20257:00 amRNSTrading update
30th Apr 20255:00 pmRNSTotal Voting Rights
24th Apr 20257:00 amRNSApproval of grant funding
11th Apr 202510:40 amRNSHolding(s) in Company
10th Apr 202512:47 pmRNSHolding(s) in Company
7th Apr 202512:35 pmRNSResult of General Meeting
31st Mar 20255:00 pmRNSTotal Voting Rights
24th Mar 20254:38 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.